Results
Methods are provided in a supplementary file. All the 24 patients with LPHS and 10 patients with IH agreed to participate and their demographic data is presented in Table 1 . Patients with LPHS were predominantly female (87%), with median age of 41 years (interquartile range 36–48). Of the patients with LPHS, 16 (67%) had microscopic hematuria, and 8 (33.3%) reported gross hematuria with exacerbations of loin pain. Nine (37%) patients reported bilateral pain, with 83% reporting opiate use with a median dose of 19 mg (0.1–78 mg). The median creatinine was 64 μmol/l (interquartile range 54.7–69.2) with albumin-to-creatinine ratio of <2.0 mg/mmol. Thirteen of 24 (54%) patients had a preceding history of kidney stones, but none had an obstructing stone on imaging at the time. There was a lag time of 6 years between the median age at onset (30 years) and at diagnosis (36 years) ( Table 1 ). Of the patients with LPHS, 10 of 24 and 5 of 24 were diagnosed with anxiety/depression and asthma, respectively, before the diagnosis of LPHS. Table 1 Cohort characteristics Demographic data LPHS Cohort ( N = 24) IH Cohort ( N = 10) Sex (Female, n %) 21 (87%) 8 (80%) Current age (yrs), median (IQR) 41 (36–48) 56 (51–61) Age at diagnosis (yrs), median (IQR) 36 (27–44) 50 (48–56) Age at onset (yrs), median (IQR) 30 (20–41) 50 (48–56) Marital status Single, n % 10 (42%) 2 (20%) Married, n % 13 (54%) 8 (80%) Divorced, n % 1 (4%) 0 (0%) Education level In school, n % 3 (12%) 0 (0%) Completed high school and a technical/vocational program, n % 6 (25%) 1 (10%) High school graduate or General Education Diploma, n % 5 (21%) 3 (30%) Less than 4 years of college with an associate degree or equivalent, n % 4 (17%) 2 (20%) College graduate (4- or 5-year program) or master’s degree, n % 6 (25%) 4 (40%) Working status Not working, n % 9 (37%) 0 (0%) Part-time, n % 9 (37%) 2 (20%) Full-time, n % 5 (21%) 7 (70%) Retired, n % 1 (4%) 1 (10%) Change in working status Quit Job, n % 9 (37%) 0 (0%) Reduced hours, n % 10 (42%) 0 (0%) None of the above, n % 5 (21%) 10 (100%) Annual Household Income (CAD) Less than $20,000, n % 6 (25%) 0 (0%) $20,000–$49,999, n % 5 (21%) 1 (10%) $50,000–$99,999, n % 4 (17%) 3 (30%) $100,000–$149,999, n % 2 (8%) 3 (30%) More than $150,000, n % 7 (29%) 3 (30%) Hematuria Microhematuria 16 (67%) 9 (90%) Macrohematuria 8 (33%) 1 (10%) Kidney stones (Yes), n % 13 (54%) 0 (0%) Kidney stone incidence, n % Never 11 (46%) 0 (0%) Less than 4 times 4 (17%) 0 (0%) ≥4 times 9 (37%) 0 (0%) Kidney stone position, n % Left kidney 3 (23%) 0 (0%) Right kidney 5 (38%) 0 (0%) Both sides 5 (38%) 0 (0%) Pain (Yes) 24 (100%) 0 (0%) Pain side, n % Left 8 (33%) 0 (0%) Right 7 (29%) 0 (0%) Both sides 9 (37%) 0 (0%) Opioids (Yes), n % 20 (83%) 0 (0%) Opioid duration (yrs), median (IQR) 4.0 (1.00–7) 0 Morphine milligram equivalent (mg), median (IQR) 19.0 (0.1–78) 0 Diabetes, n % 1 (4%) 0 (0%) Hypertension, n % 3 (12%) 3 (30%) Family history of isolated hematuria (Yes), n % 6 (24%) 2 (20%) Family history of kidney stones (Yes), n % 15 (62%) 5 (50%) CAD, Canadian dollars; IH, isolated hematuria; IQR, interquartile range; LPHS, loin pain hematuria syndrome.
Cohort characteristics
CAD, Canadian dollars; IH, isolated hematuria; IQR, interquartile range; LPHS, loin pain hematuria syndrome.
Patients with LPHS in comparison with those with IH had more irritable bowel syndrome (37% vs. 10%), depression/anxiety (58% vs. 20%), migraine (50% vs. 20%), history of frequent kidney infections (37.5% vs. 10%), and history of physical assault (29% vs. 10%). There was also a greater family history of chronic pain (21% vs. 30%), chronic fatigue syndrome (16.7% vs. 0%), and mood disorders (62.5% vs. 30%) ( Table 2 ). We further subdivided the patients into 2 subgroups (patients with preexisting stones vs. spontaneous onset) and did not identify any notable differences ( Supplementary Table S1 ). Analysis of the pedigree charts revealed that 2 patients with LPHS (LPHS-17 and -21) had a history of LPHS in their family. In addition, 6 patients with LPHS (LPHS-01, -02, -04, -05, -11, and -21) and 2 patients with IH (HEMA-01 and -05) had a history of IH in their families ( Figure 1 ). Table 2 Comorbidities and family history of diseases Comorbidities/family history of disease ( n , %) LPHS ( N = 24) IH ( N = 10) Diabetes 1 (4.2%) 0 (0%) Blood pressure 3 (12.5%) 3 (30%) Asthma 5 (20.8%) 1 (10%) Polycystic ovarian disease 3 (12.5%) 0 (0%) Endometriosis 6 (25%) 1 (10%) Kidney stone 13(54.2%) 0 (0%) Chronic fatigue syndrome 3 (12.5%) 0 (0%) Gastrointestinal disease/IBS 9 (37.5%) 1 (10%) Trauma to the abdomen and back 5 (20.8%) 0 (0%) Anxiety/depression 14 (58.3%) 2 (20%) Migraine 12 (50%) 2 (20%) Thyroid 4 (16.7%) 2 (20%) Rheumatological conditions 2 (8.3%) 0 (0%) History of frequent kidney infections 9 (37.5%) 1 (10%) Hysterectomy 7 (29.2%) 1 (10%) History of physical/sexual assault 7 (29.2%) 1 (10%) A parent suffering from a chronic disease or chronic pain 5 (20.8%) 3 (30%) Family history of kidney stones 15 (62.5%) 5 (50%) Family history of IH 6 (24%) 2 (20%) Family history of LPHS 2 (8.3%) 0 (0%) Family history of hypertension 16 (66.7%) 9 (90%) Family history of diabetes 14 (58.3%) 6 (60%) Family history of gout 6 (25%) 3 (30%) Family history of chronic fatigue syndrome 4 (16.7%) 0 (0%) Family history of asthma 10 (41.7%) 3 (30%) Family history of mood (depression/anxiety) 15 (62.5%) 3 (30%) Family history of allergy 15 (62.5%) 5 (50%) Painful uterine bleeding ≥7 (on a scale of 1–10) 11 (45.8%) 5 (50%) IBS, irritable bowel syndrome; IH, isolated hematuria; LPHS, loin pain hematuria syndrome. Figure 1 Pedigree analysis of selected patients with a positive family history. Roman numbers represent the generations of the family. The proband is indicated by an arrow. a, anxiety; ADHD, attention deficit hyperactivity disorder; as, asthma; ch, high cholesterol; d, depression; di, diabetes; f, fibroids; g, gout; HBP, high blood pressure; k, kidney stones; m, migraine; r, other renal disease (not IH or LPHS).
Comorbidities and family history of diseases
IBS, irritable bowel syndrome; IH, isolated hematuria; LPHS, loin pain hematuria syndrome.
Pedigree analysis of selected patients with a positive family history. Roman numbers represent the generations of the family. The proband is indicated by an arrow. a, anxiety; ADHD, attention deficit hyperactivity disorder; as, asthma; ch, high cholesterol; d, depression; di, diabetes; f, fibroids; g, gout; HBP, high blood pressure; k, kidney stones; m, migraine; r, other renal disease (not IH or LPHS).
Disclosure
All the authors declared no competing interest.
Discussion
In this paper, we present a thorough and comprehensive assessment of phenotypic characteristics and pedigree charts of 24 patients with LPHS and 10 patients with IH. To our knowledge, this is the first study to report 2 patients with LPHS with a history of LPHS in their families. In addition, 6 patients with LPHS and 2 patients with IH had a history of painless hematuria in their families. In comparison with patients with IH, patients with LPHS had greater family history of mood disorders, chronic fatigue syndrome, painful uterine bleeding, and allergies. This information, to our knowledge, has not been reported before. Similarly, patients with LPHS were likely (in comparison to IH) to have comorbidities such as anxiety/depression, migraine, irritable bowel syndrome, chronic fatigue syndrome, and prior history of physical/sexual assault.
We found that patients with LPHS fell into 2 distinct categories. One group had premorbid history of renal stone disease (58%) and the second group had spontaneous onset with no precipitating triggers. Although a third phenotype of patients with LPHS with exercise being the trigger has been reported, we did not see any cases in our cohort. We attempted to have an in-depth look at these 2 groups, but we could not ascertain any differences in the comorbidities or their family history.
As reported in previous cohorts, a high proportion of our patients were predominantly female (87.5%) and the majority of our patients with LPHS were <30 years (54%). The patients with IH were identified during routine health check-ups, whereas patients with LPHS needed repetitive visits with numerous health care providers and emergency room visits for a mean of 6 years before being diagnosed. Of our patients, 58% had a premorbid history of renal stones. The presence of nonobstructive kidney stones on imaging at presentation has been reported by other groups. Leaker et al. 3 reported 10 of 25 patients had a prior history of renal stones. Similarly, Greenwell et al. 4 reported 10 of 32 patients with urinary tract stones.
Of the patients with LPHS in our cohort, 37.5% reported frequent urinary tract infections with intensification of pain during episodes. Our findings were similar to Goroszeniuk et al. 5 (25%) whereas Sheil et al. 6 reported 16% with recurrent urinary tract infections. Of our patients with LPHS, 5 of 24 reported asthma preceding the diagnosis of LPHS. Our findings are similar to the series by Bass et al. where 4 of 21 patients also reported asthma. 7 Of our cohort, 6 of 24 (25%) had a concurrent diagnosis of endometriosis and there have been previous reports that have reported endometriosis. 8 In our cohort, 50% of patients with LPHS and 20% of those with IH gave a history of migraine. This association has been previously reported with Bass et al. 8
We noticed that 30% of patients with LPHS had a prior history of physical/sexual assault, a factor known to predispose them to chronic pain syndromes. This association, to our knowledge, has not been identified earlier. Chronic pain is often accompanied by anxiety/depression, sleep, fatigue, and cognitive decline that impact patients’ quality of life. Zubair et al. 9 reported anxiety and depression in 12 of 21 patients. In our cohort, 14 of 24 (60%) had a history of anxiety and depression with 11 of 14 patients being diagnosed before the diagnosis of LPHS. We observed that 12.5% of patients had chronic fatigue syndrome, and 37.5% of patients had irritable bowel syndrome. We relied on questionnaires for data collection which we acknowledge can result in reporting bias and is a limitation of the study. The sample size of 24 patients, although it limits generalizability of findings, is definitely a sufficient number for evaluation of a rare disease. Although the participants were all followed up with in a single clinic, we do get referrals from across Canada.
We are the first group to conduct a detailed evaluation of physical traits, associated comorbidities, and family genomic links. Phenotyping is the first step in gaining a deeper understanding of disease characteristics. However, there are still gaps in our understanding of this rare and debilitating disease. The next logical step will be to interrogate the genes that encode the filtration barrier. By linking phenotypes to genotypes, we hope to establish a more comprehensive clinical picture and help aid decision making.
Introduction
Hematuria is quite common and accounts for over 20% of urology evaluations. 1 In screening studies among healthy volunteers, the prevalence ranges from 2.5% to 31%. 2 Although isolated hematuria (IH) is a common occurrence, the reported prevalence of loin pain hematuria syndrome (LPHS) is 1 in 10,000. The low prevalence of LPHS is likely due to the condition being a diagnosis of exclusion and therefore being underappreciated and underdiagnosed. Patients with IH and patients with LPHS share common features such as the absence of urological disease and the presence of glomerular hematuria. For reasons that are as yet unclear, patients with LPHS experience debilitating unilateral or bilateral flank pain, originating from the kidneys.
Is LPHS an “umbrella term” for all patients with glomerular hematuria and pain with differing etiopathogenesis or is it an independent entity. Is it a kidney disorder or “renal migraine” where neurogenic stimuli lead to the release of vasoactive neuropeptides or is it a somatization disorder. As part of disentangling any unexplained illness, it is essential to perform a thorough phenotype assessment (physical characteristics, family history, and comorbidities). Phenotyping allows us to stratify patients and understand disease mechanisms. In this paper, we performed detailed phenotype assessment and pedigree analysis on patients with LPHS and compared them with patients with IH.